2027 Formulary Changes: Express Scripts
Posted on November 19, 2026
The following is an analysis of the Express Scripts (ESI) 2027 formulary changes for the National Preferred Formulary (NPF), effective January 1, 2027. PSG’s clinical and analytics team evaluated the changes, including an impact analysis using claims data from PSG’s book of business, to provide an overview of the most important considerations.
Notable Express Scripts Formulary Changes
- Express Scripts’ 2027 National Preferred Formulary changes include 26 new drug exclusions, compared with 48 in 2026
- Diabetes changes are limited to select rapid-acting insulins and high-cost metformin products
- Generic and biosimilar changes will narrow some preferred treatment options
- Oncology and cardiomyopathy exclusions warrant particular attention to clinical needs and coverage exceptions
| National Preferred Formulary | |
|---|---|
| New Exclusions for January 2027 | 26 |
| Number of Exclusions – Specialty Drugs | 8 |
| New Multi-Source Brand Exclusions for January 2026 | 5 |
| % Members Impacted | 0.2% |
| Total Drug Spend Impact | 0.02% |
Express Scripts Formulary Change Impact
Compared with 2026, ESI’s 2027 changes are a lighter lift for payers: 26 new exclusions versus 48 in 2026, including eight specialty drugs. Based on PSG’s book of business, the changes affect about 0.2% of members and 0.02% of total drug spend. Rather than sweeping category shifts, ESI is narrowing preferred options in several therapeutic categories and excluding select high-cost therapies. The following sections highlight the most important considerations for payers and affected members.
Non-Specialty Categories
Notable non-specialty changes include exclusions affecting migraine treatment and other high-cost therapies.
ESI will exclude brand Zomig and generic zolmitriptan nasal sprays, used for the acute treatment of migraines, leaving sumatriptan nasal spray as the only preferred triptan nasal spray. Both drugs are available as generics, but sumatriptan costs about half as much as zolmitriptan. Both are considered highly effective, but individual treatment responses vary, so payers should prepare for questions and coverage requests from members currently using zolmitriptan.
ESI will also exclude Addyi, a once-daily oral tablet used for the treatment of menopause-related sexual dysfunction in women, impacting about 0.0018% of members, according to PSG’s book of business. In late 2025, the FDA expanded Addyi’s indication to include postmenopausal women, and the expansion was followed by a price increase that more than doubled the drug’s monthly cost, from $962 to $2,027. The preferred alternative, Vyleesi, costs plans about half as much, but it is a subcutaneous injection used as needed, up to eight times per month. Because some members may prefer an oral tablet over an injection, this change could be disruptive despite its small footprint.
Diabetes Changes
There are minimal diabetes coverage changes, limited to select rapid-acting insulins and high-cost generic products. Lyumjev will be excluded, further narrowing preferred options in the rapid-acting insulin category. Preferred alternatives will include Humalog and Merilog, a biosimilar to NovoLog.
ESI will also exclude select high-cost generic metformin strengths (625mg and 750mg), which cost plans more than $5,000 per 90-day supply. Standard generic metformin (500mg, 850mg, and 1,000mg) costs plans $10 or less for the same supply, and members can switch easily. Neither diabetes change is expected to cause significant member disruption.
Biosimilars and Specialty Generics
Generic Xeljanz and Xeljanz XR entered the market in mid-2026 at very low costs, paving the way for savings in a brand-dominated inflammatory condition category. Express Scripts will exclude the brand products and prefer their much lower-cost generic alternatives.
Additional biosimilar changes include the exclusion of Selarsdi, a Stelara biosimilar. Preferred alternatives for Humira and Stelara will continue to include ESI’s private-label biosimilars and two other biosimilar options for each.
Oncology
ESI will narrow preferred options in the Bruton’s tyrosine kinase (BTK) inhibitor category by excluding Brukinsa. Jaypirca will remain excluded. Depending on the indication, preferred alternatives may include Calquence or Imbruvica. Because oncology treatment is highly individualized, payers should confirm that a clear coverage exception process is in place for members whose excluded drug is medically necessary.
Other Exclusions
The 2027 formulary changes also affect newer treatments for two serious heart conditions. In both categories, Express Scripts will prefer existing therapies over newer options. While no direct head-to-head clinical trials have been conducted to compare their efficacy, each drug brings a distinct set of clinical and practical advantages.
Express Scripts will exclude Attruby and Amvuttra for hereditary transthyretin amyloid cardiomyopathy (hATTR-CM), with Vyndamax as the preferred alternative. The products differ in administration: Attruby is taken orally twice daily, Amvuttra is administered by subcutaneous injection every three months, and Vyndamax is taken orally once daily. Amvuttra will remain covered for the indication of polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Amvuttra’s annual cost of about $477K is significantly higher than that of Attruby and Vyndamax, which each cost roughly $245K–$268K per year. hATTR-CM affects an estimated 100K–120K people in the U.S. and, if left untreated, can lead to heart failure and death.
Express Scripts will also exclude Myqorzo, approved by the FDA in December 2025, in favor of Camzyos. Both treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), an inherited condition in which thickened heart muscle reduces blood flow from the heart.
Both drugs are cardiac myosin inhibitors with a similar cost of more than $390 per day. Camzyos has a first-to-market advantage, with established utilization and provider workflows, while Myqorzo offers some safety, pharmacokinetic, and logistical advantages. An estimated 750K people in the U.S. have oHCM.
Final Thoughts
Express Scripts’ 2027 formulary changes are lighter than in 2026, with fewer exclusions and minimal overall member and drug spend impact. The changes focus on select high-cost therapies and narrower preferred options in several categories. Oncology and cardiomyopathy exclusions warrant particular attention to individual clinical needs and coverage exceptions. If any of these areas are relevant to your member population, they are worth monitoring as you head into 2027.
Need help navigating 2027 formulary changes? PSG has the unbiased clinical and market expertise you need. Contact us today to learn more.